Indobufen in the prevention of complications in orthopaedic surgery: A pharmacoeconomic assessment

B. Borghi, C. Lazzaro

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This Italian prospective multicentre trial was conducted between 1992 and 1994 to assess how antithrombotic prophylaxis influences the need for homologous blood transfusion, and the incidence of deep venous thrombosis (DVT) and pulmonary thromboembolism in patients undergoing major orthopaedic surgery. The patients (n = 980; 321 males and 659 females) received antithrombotic prophylaxis comprising haemodilution together with one of the following pharmacological regimens: indobufen (INDO) (n = 688); calcium heparin (CaH) (n = 200); low molecular weight heparin (LMWH) (n = 112). Patients who received prophylaxis with INDO experienced less frequent postoperative complications (haematomas and DVT) compared with those who received CaH or LMWH (p = 0.0001), as well as requiring a significantly shorter postoperative hospital stay (p = 0.04) and a significantly reduced need for homologous transfusion (p = 0.03). A cost-effectiveness analysis carried out using this clinical evidence has shown INDO to be a 'cost-saving' drug when compared with CaH and LMWH in the prophylaxis and treatment of orthopaedic postoperative complications. A sensitivity analysis performed by varying the hospitalisation cost according to two different hypotheses confirmed these findings. These data may have important implications for the management of patients with venous thromboembolism.

Original languageEnglish
Pages (from-to)129-144
Number of pages16
JournalBritish Journal of Medical Economics
Volume10
Issue number2
Publication statusPublished - 1996

Fingerprint

Pharmaceutical Economics
Orthopedics
Low Molecular Weight Heparin
Venous Thromboembolism
Venous Thrombosis
Hemodilution
Drug Costs
Pulmonary Embolism
Blood Transfusion
Hematoma
Multicenter Studies
Cost-Benefit Analysis
Length of Stay
Hospitalization
Pharmacology
Costs and Cost Analysis
indobufen
Incidence
calcium heparin
Therapeutics

Keywords

  • Cost-effectiveness analysis
  • Indobufen
  • Othopaedic surgery
  • Pharmacoeconomics

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Indobufen in the prevention of complications in orthopaedic surgery : A pharmacoeconomic assessment. / Borghi, B.; Lazzaro, C.

In: British Journal of Medical Economics, Vol. 10, No. 2, 1996, p. 129-144.

Research output: Contribution to journalArticle

@article{d918a2e1ec9745aabce67be7f27d20d0,
title = "Indobufen in the prevention of complications in orthopaedic surgery: A pharmacoeconomic assessment",
abstract = "This Italian prospective multicentre trial was conducted between 1992 and 1994 to assess how antithrombotic prophylaxis influences the need for homologous blood transfusion, and the incidence of deep venous thrombosis (DVT) and pulmonary thromboembolism in patients undergoing major orthopaedic surgery. The patients (n = 980; 321 males and 659 females) received antithrombotic prophylaxis comprising haemodilution together with one of the following pharmacological regimens: indobufen (INDO) (n = 688); calcium heparin (CaH) (n = 200); low molecular weight heparin (LMWH) (n = 112). Patients who received prophylaxis with INDO experienced less frequent postoperative complications (haematomas and DVT) compared with those who received CaH or LMWH (p = 0.0001), as well as requiring a significantly shorter postoperative hospital stay (p = 0.04) and a significantly reduced need for homologous transfusion (p = 0.03). A cost-effectiveness analysis carried out using this clinical evidence has shown INDO to be a 'cost-saving' drug when compared with CaH and LMWH in the prophylaxis and treatment of orthopaedic postoperative complications. A sensitivity analysis performed by varying the hospitalisation cost according to two different hypotheses confirmed these findings. These data may have important implications for the management of patients with venous thromboembolism.",
keywords = "Cost-effectiveness analysis, Indobufen, Othopaedic surgery, Pharmacoeconomics",
author = "B. Borghi and C. Lazzaro",
year = "1996",
language = "English",
volume = "10",
pages = "129--144",
journal = "British Journal of Medical Economics",
issn = "0962-1423",
publisher = "PJB Publications Ltd.",
number = "2",

}

TY - JOUR

T1 - Indobufen in the prevention of complications in orthopaedic surgery

T2 - A pharmacoeconomic assessment

AU - Borghi, B.

AU - Lazzaro, C.

PY - 1996

Y1 - 1996

N2 - This Italian prospective multicentre trial was conducted between 1992 and 1994 to assess how antithrombotic prophylaxis influences the need for homologous blood transfusion, and the incidence of deep venous thrombosis (DVT) and pulmonary thromboembolism in patients undergoing major orthopaedic surgery. The patients (n = 980; 321 males and 659 females) received antithrombotic prophylaxis comprising haemodilution together with one of the following pharmacological regimens: indobufen (INDO) (n = 688); calcium heparin (CaH) (n = 200); low molecular weight heparin (LMWH) (n = 112). Patients who received prophylaxis with INDO experienced less frequent postoperative complications (haematomas and DVT) compared with those who received CaH or LMWH (p = 0.0001), as well as requiring a significantly shorter postoperative hospital stay (p = 0.04) and a significantly reduced need for homologous transfusion (p = 0.03). A cost-effectiveness analysis carried out using this clinical evidence has shown INDO to be a 'cost-saving' drug when compared with CaH and LMWH in the prophylaxis and treatment of orthopaedic postoperative complications. A sensitivity analysis performed by varying the hospitalisation cost according to two different hypotheses confirmed these findings. These data may have important implications for the management of patients with venous thromboembolism.

AB - This Italian prospective multicentre trial was conducted between 1992 and 1994 to assess how antithrombotic prophylaxis influences the need for homologous blood transfusion, and the incidence of deep venous thrombosis (DVT) and pulmonary thromboembolism in patients undergoing major orthopaedic surgery. The patients (n = 980; 321 males and 659 females) received antithrombotic prophylaxis comprising haemodilution together with one of the following pharmacological regimens: indobufen (INDO) (n = 688); calcium heparin (CaH) (n = 200); low molecular weight heparin (LMWH) (n = 112). Patients who received prophylaxis with INDO experienced less frequent postoperative complications (haematomas and DVT) compared with those who received CaH or LMWH (p = 0.0001), as well as requiring a significantly shorter postoperative hospital stay (p = 0.04) and a significantly reduced need for homologous transfusion (p = 0.03). A cost-effectiveness analysis carried out using this clinical evidence has shown INDO to be a 'cost-saving' drug when compared with CaH and LMWH in the prophylaxis and treatment of orthopaedic postoperative complications. A sensitivity analysis performed by varying the hospitalisation cost according to two different hypotheses confirmed these findings. These data may have important implications for the management of patients with venous thromboembolism.

KW - Cost-effectiveness analysis

KW - Indobufen

KW - Othopaedic surgery

KW - Pharmacoeconomics

UR - http://www.scopus.com/inward/record.url?scp=0029790877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029790877&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029790877

VL - 10

SP - 129

EP - 144

JO - British Journal of Medical Economics

JF - British Journal of Medical Economics

SN - 0962-1423

IS - 2

ER -